Thermo Fisher Scientific (TMO) Q3 2026 Earnings Call: Q&A Summary

Q: Tycho Peterson with Jefferies asked for a state of the union on end markets and whether the improvement is broad or concentrated.

A: Marc Casper noted that the momentum from the second quarter continued. Pharma and biotech delivered high single-digit growth, academic and government was flat, industrial and applied grew high single digits, and diagnostics and healthcare grew low single digits.

Q: Dan Arias with Stifel asked if the biotech recovery is expanding into the reagent segment.

A: Marc Casper explained that clinical research and channel activity improved first, and he expects high-tech reagents to be the next phase of recovery for that customer base.

Q: Matt Larew with William Blair asked about performance in Lab Solutions and the status of bioproduction.

A: Marc Casper noted that while bioscience and genetic science reagents remain muted, bioproduction remains the strongest growing business, though comparisons are normalizing.

Q: Dan Brennan with TD Cowen asked what drove the third quarter beat beyond the Patheon business.

A: Jim Meyer cited timing benefits in pharma services, strong performance in Analytical Instruments, particularly electron microscopy in semiconductor applications, and low double-digit growth in China.

Q: Tycho Peterson with Jefferies asked about the path to 8% to 10% growth in pharma and the role of AI.

A: Marc Casper stated that customer confidence has increased due to resolved government negotiations and strong pipeline science. He added that AI improves customer ROI, which creates a virtuous cycle of investment.

Q: Doug Schenkel with UBS asked if AI drives incremental demand and could increase the long-term organic growth algorithm.

A: Marc Casper said AI enables better medicines, which drives demand. He reiterated that 7% is a reasonable organic growth outlook, not a cap.

Q: Matt Larew with William Blair asked how to think about monetizing AI tools versus using them to maintain or gain share.

A: Marc Casper explained that AI helps design scientific workflows, which drives demand for instruments and reagents while also improving services like clinical research.

Q: Dan Brennan with TD Cowen asked if management could size the potential benefit of AI.

A: Marc Casper said they will provide more detail on February 2 and at the next Investor Day, but they are bullish on the implications for customers and patients.

Q: Evie Koslosky with Goldman Sachs asked about the value proposition of AI in clinical research.

A: Marc Casper said AI helps shave time and improve success rates, which is unique to their capabilities and is driving strong market momentum.

Q: Jack Meehan with Operon Research asked about the phasing from the third to the fourth quarter.

A: Jim Meyer explained that the third quarter had some timing benefits in pharma services, but the fourth quarter guidance remains consistent with their second-half outlook.

Q: Jack Meehan with Operon Research asked for thoughts on 2027 and progressing toward the higher end of the 3% to 6% growth range.

A: Marc Casper said they look at end-market evolution and internal actions to set guidance, with the goal of returning to normal growth.

Q: Dan Arias with Stifel asked about the organic contribution of the Solventum business.

A: Jim Meyer said the business is performing well as a mid- to high single-digit grower with strong customer adoption.

Q: Doug Schenkel with UBS asked about key investments made during the downturn that position the company for recovery.

A: Marc Casper highlighted investments in innovation, pharma services, clinical research, and acquisitions like Clario and filtration and separation, which position them for 7% organic growth.

Q: Evie Koslosky with Goldman Sachs asked about the durability of bioprocessing momentum and the impact of design centers.

A: Marc Casper stated the business is a high single-digit to low double-digit grower, and design centers allow customers to work with scientists to develop processes and scale from lab to production.